TAK logo

TAKTakeda Pharmaceutical Co Ltd (ADR)

$15.65
$0.04
(0.25%)
Today
Closed $15.68
$0.03
(0.19%)
After Hours
Updated: 05:11 PM EDT
Reported EarningsMay 13
Mkt Cap$49.67B
Vol2.42M
News
all
press releases
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohns...
Business Wire
News Placeholder
More News
News Placeholder
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
Zacks
News Placeholder
Takeda Pharmaceutical is Now Oversold (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
News Placeholder
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Zacks
News Placeholder
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
Zacks
News Placeholder
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
Zacks
News Placeholder
Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA or lubiprostone...
Nasdaq News: Markets
News Placeholder
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic equivalents ended today when a jury returned a verdict finding the pharma...
Business Wire
News Placeholder
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management...
Business Wire
News Placeholder
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Zacks
<
1
2
...
>

Advertisement|Remove ads.